Please login to the form below

Not currently logged in
Email:
Password:

immunotherapies

This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.

Novartis buys cancer specialist Endocyte for $2.1bn

It’s worth pointing out that buying Endocyte also gives Novartis an additional platform in CAR-T cancer immunotherapy to complement its current assets, including already-marketed therapy Kymriah (tisagenlecleucel) for

Latest news

More from news
Approximately 68 fully matching, plus 377 partially matching documents found.

Latest Intelligence

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma. ... Open-minded culture. Like the new HQ’s

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    AZ isn’t a frontrunner overall in lung cancer immunotherapy – MSD consolidated its global lead by gaining a groundbreaking approval of Keytruda in China in July – but AZ has an ace

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The company has a PD-1 cancer immunotherapy, tislelizumab, in development in China, and believes it can compete in the market alongside multinationals MSD (Merck in the US) and BMS and

  • Made in China Made in China

    It has just submitted its PD-1 immunotherapy candidate tislelizumab with China’s regulator, and also has a late-stage BTK inhibitor to challenge J&J’s Imbruvica with a potential

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Cancer immunotherapy: What's on the horizon? Old and new therapies. Cancer remains one of the world’s top healthcare challenges, but over the years our ability to treat the disease ... and ovarian cancer, and some tumours such as pancreatic and

More from intelligence
Approximately 1 fully matching, plus 45 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 43 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 12 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics